Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 9, 2013, Pages 1151-1160

  Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

Diarrhea; Intestinal motor function; Irritable bowel syndrome; Pharmacological treatments

Indexed keywords

ALOSETRON; AMINOSALICYLIC ACID; AMITRIPTYLINE; ASIMADOLINE; AST 120; CODEINE; COLESEVELAM; COLESTYRAMINE; CROMOGLYCATE DISODIUM; DESIPRAMINE; DIPHENOXYLATE; DOXEPIN; DULOXETINE; FLUPHENAZINE; IMIPRAMINE; KETOTIFEN; LOPERAMIDE; LX 1031; MEBEVERINE; MESALAZINE; NORTRIPTYLINE; PLACEBO; PROBIOTIC AGENT; RAMOSETRON; RIFAXIMIN; TOFISOPAM; TRIMIPRAMINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BLADDER DYSFUNCTION; BLOOD BRAIN BARRIER; COLON MOTILITY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TRANSIT; GENETIC VARIABILITY; GLAUCOMA; HUMAN; INTESTINAL SECRETION; INTESTINE FUNCTION; IRRITABLE COLON; ISCHEMIC COLITIS; LOW DRUG DOSE; META ANALYSIS (TOPIC); NONHUMAN; PALLIATIVE THERAPY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK MANAGEMENT; TACHYCARDIA;

ANIMALS; ANTIDIARRHEALS; DIARRHEA; DRUG DESIGN; GASTROINTESTINAL AGENTS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IRRITABLE BOWEL SYNDROME; PATIENT EDUCATION AS TOPIC;

EID: 84877911333     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.794223     Document Type: Review

References (79)

1. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-21.e4
3. Camilleri M. Mechanisms in IBS: something old, something new, something borrowed. Neurogastroenterol Motil 2005;17:311-16
4. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012;367:1626-35
5. Oddsson E, Rask-Madsen J, Krag E. A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scand J Gastroenterol 1978;13:409-16
6. Delvaux M, Louvel D, Mamet JP, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharm Ther 1998;12:849-55
7. Viramontes BE, Camilleri M, McKinzie S, et al. Gender related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;92:2671-6
8. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3-receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-59
9. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035-40
10. Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999;13:1419-27
11. Chang L, Ameen VZ, Dukes GE, et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005;100:115-23
12. Andresen V, Montori VM, Keller J, et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008;6:545-55
13. Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006;101:1069-79
14. Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol 2010;105:866-75
15. Cremonini F, Nicandro JP, Atkinson V, et al. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther 2012;36:437-48
16. Vassallo M, Camilleri M, Phillips SF, et al. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992;102:102-8
17. Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008;6:772-81
18. Cann PA, Read NW, Holdsworth CD, et al. Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 1984;29:239-47
19. Awouters F, Megens A, Verlinden M, et al. Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci 1993;38:977-95
20. Gattuso JM, Kamm MA. Adverse effects of drugs used in the management of constipation and diarrhoea. Drug Saf 1994;10:47-65
21. Penfold D, Volans GN. Overdose from Lomotil. Br Med J 1977;2:1401-2
22. Read M, Read NW, Barber DC, et al. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci 1982;27:807-14
23. Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome- A double-blind placebo controlled study. Scand J Gastroenterol 1987;130:77-80
24. Efskind PS, Bernklev T, Vatn MH. A double-blind, placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996;31:463-8
25. Thaysen EH, Pedersen L. Idiopathic bile salt catharsis. Gut 1976;17:965-70
26. Wedlake L, A'Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009;30:707-17
27. Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012;10:1009-15.e3
28. Sciarretta G, Fagioli G, Fumo A, et al. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut 1987;28:970-5
29. Brydon WG, Nyhlin H, Eastwood MA, et al. Serum 7 alpha-hydroxy-4- cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol 1996;8:117-23
30. Camilleri M, Prather CM. The irritable bowel syndrome: mechanisms and a practical approach to management. Ann Intern Med 1992;116:1001-8
31. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010;8:159-65
32. Wong BS, Camilleri M, Carlson PJ, et al. Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci 2012;57:1222-6
33. Heefner JD, Wilder RM, Wilson JD. Irritable colon and depression. Psychosomatics 1978;19:540-7
34. Hislop IG. Psychological significance of the irritable colon syndrome. Gut 1971;12:452-7
35. Lancaster-Smith MJ, Prout BJ, Pinto T, et al. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity. Acta Psychiatr Scand 1982;66:33-41
36. Greenbaum DS, Mayle JE, Vanegeren LE, et al. The effects of desipramine on IBS compared with atropine and placebo. Dig Dis Sci 1987;32:257-66
37. Myren J, Lovland B, Larssen S-E, et al. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1984;19:835-43
38. Ritchie JA, Truelove SC. Comparison of various treatments for irritable bowel syndrome. Br Med J 1980;281:1317-19
39. Vahedi H, Merat S, Momtahen S, et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008;27:678-84
40. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31
41. Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011;8):CD003460
42. Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-78
43. Masand PS, Gupta S, Schwartz TL, et al. Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome? Psychosomatics 2002;43:451-5
44. Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther 2010;32:1221-33
45. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-32
46. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32
47. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012;107:28-35
48. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-73
49. Lobo B, Vicario M, Martinez C, et al. Clinical benefit in IBS after disodium cromoglycate involves mast cell-mediated recovery of healthy-like innate immunity genes expression profile in the jejunal mucosa. Gastroenterology 2009;136(Suppl 1):156
50. Lobo B, Vicario M, Martinez C, et al. Clinical improvement in IBS after disodium cromoglycate involves mast cell-mediated toll-like receptor signaling downregulation. Gastroenterology 2011;140(Suppl 1):499-500
51. Leri O, Tubili S, De Rosa FG, et al. Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate. Inflammopharmacology 1997;5:153-8
52. Gay J, Ressayre L, Garcia-Villar R, et al. Alteration of CCK-induced satiety in post-Nippostrongylus brasiliensis-infected rats. Brain Behav Immun 2003;17:35-42
53. Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010;59:1213-21
54. Corinaldesi R, Stanghellini V, Cremon C, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009;30:245-52
55. Andrews CN, Griffiths TA, Kaufman J, et al. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011;34:374-83
56. Dorofeyev AE, Kiriyan EA, Vasilenko IV, et al. Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome. Clin Exp Gastroenterol 2011;4:141-53
57. Tuteja AK, Fang JC, Al-Suqi M, et al. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome- A pilot study. Scand J Gastroenterol 2012;47:1159-64
58. Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130:34-43
59. Faure C, Patey N, Gauthier C, et al. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology 2010;139:249-58
60. Hoffman JM, Tyler K, MacEachern SJ, et al. Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 2012;142:844-54
61. Freiman J, Jackson J, Frazier KS, et al. LX1031: inhibition of 5-HT synthesis as a new target in the management of irritable bowel syndrome (IBS). Neurogastroenterol Motil 2009;21:250
62. Brown PM, Drossman DA, Wood AJ, et al. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology 2011;141:507-16
63. Hirata T, Funatsu T, Keto Y, et al. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacology 2007;15:5-9
64. Hirata T, Keto Y, Nakata M, et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil 2008;20:557-65
65. Matsueda K, Harasawa S, Hongo M, et al. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008;77:225-35
66. Matsueda K, Harasawa S, Hongo M, et al. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 2008;43:1202-11
67. Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 2011;23:1098-104
68. Anderson K, Fischer L. Prevention of GI absorption of bacterial toxins: an in vitro evaluation of the potential for prophylactic use of a novel oral adsorbent (AST-120). Gastroenterology 2008;134(Suppl 1):A-675
69. Anderson K, Tomiyama S, Nitta T. A novel, engineered carbon microsphere product for use in chronic inflammatory bowel disease and liver dysfunction. Gastroenterology 2008;134(Suppl 1):A-675
70. Tack JF, Miner PB Jr, Fischer L, et al. Randomised clinical trial: the safety and efficacy of AST-120 in non-onstipating irritable bowel syndrome- A double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011;34:868-77
71. Leventer SM, Kucharik RF, Keogh JC, et al. The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease. Am J Gastroenterol 2004;99(Suppl 5):S279
72. Leventer SM, Raudibaugh K, Frissora CL, et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008;27:197-206
73. Delvaux M, Beck A, Jacob J, et al. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:237-46
74. Delgado-Aros S, Chial HJ, Camilleri M, et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol 2003;284:G558-66
75. Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:239-49
76. Spiegel B, Strickland A, Naliboff BD, et al. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008;103:2536-44
77. Trentacosti AM, He R, Burke LB, et al. Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol 2010;105:731-5
78. Degen LP, Phillips SF. How well does stool form reflect colonic transit? Gut 1996;39:109-13
79. Camilleri M. Pharmacology of the new treatments for lower gastrointestinal disorders and irritable bowel syndrome. Clin Pharmacol Ther 2012;91:44-59